B Cell Lymphoma
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
News
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphoma
Mainly low-grade toxic effects were seen on treatment with Hu5F9-G4 and rituximab in the study of relapsed and refractory patients.
Article
Collaboration is key to bridging the AYA cancer care divide
Article
Game changers in pediatric cancer
News
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphoma
The risk of line-associated complications was significantly higher with dose-adjusted EPOCH-R therapy, compared with R-CHOP, in patients with...
News
First-line bortezomib prolongs survival in MCL
The survival benefits are promising with the addition of bortezomib, but there was no significant difference among high-risk patients.
News
Combo can prolong overall survival in MCL
Final results of a phase 3 trial suggest bortezomib plus rituximab and chemotherapy can significantly improve overall survival (OS) in transplant-...
News
Older age predicts mortality after alloHCT in NHL, but not relapse
The researchers said older age was an independent risk factor for nonrelapse mortality.
News
Study challenges LVEF assessment before DLBCL treatment
Preliminary findings have researchers questioning why cardiac testing is routine before administering chemotherapy containing doxorubicin.
News
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.